Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia

Schizophrenia Research

Volumn 146, Issue 1-3, 2013, Pages 224-230

  Egan, Michael F ^a   Zhao, Xin ^a   Gottwald, Regina ^a   Harper Mozley, Lyn ^a   Zhang, Ying ^a   Snavely, Duane ^a   Lines, Christopher ^a   Michelson, David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cognition; Histamine subtype 3 receptor; MK 0249; Randomized trial; Schizophrenia

Indexed keywords

HALOPERIDOL; HISTAMINE H3 RECEPTOR AGONIST; MK 0249; OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE; SERTINDOLE; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; ANXIETY; ARTICLE; ATTENTION; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA BATTERY; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISODIC MEMORY; FEMALE; HUMAN; INSOMNIA; IRRITABILITY; LIMB PAIN; MALE; MULTICENTER STUDY; NAUSEA; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; OUTPATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SINGLE BLIND PROCEDURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; WORKING MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; QUINAZOLINONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875917946     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.02.030     Document Type: Article

References (40)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders. (DSM-IV) - Text Revision 2000, American Psychiatric Press, Washington, DC. 4th ed.
2. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a powerful and practical approach to multiple testing. J. R. Stat. Soc. Ser. B 1995, 57:289-300.
3. Brioni J.D., Esbenshade T.A., Garrison T.R., Bitner S.R., Cowart M.D. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J. Pharmacol. Exp. Ther. 2011, 336:38-46.
4. Bryson G. Initial and final work performance in schizophrenia: cognitive and symptom predictors. J. Nerv. Ment. Dis. 2003, 191:87-92.
5. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S., Leon A.C., Nuechterlein K.H., Laughren T., Levin R., Stover E., Fenton W., Marder S.R. A summary of the FDA-NIMHMATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 2005, 31:5-19.
6. Buchanan R.W., Keefe R.S., Lieberman J.A., Barch D.M., Csernansky J.G., Goff D.C., Gold J.M., Green M.F., Jarskog L.F., Javitt D.C., Kimhy D., Kraus M.S., McEvoy J.P., Mesholam-Gately R.I., Seidman L.J., Ball M.P., McMahon R.P., Kern R.S., Robinson J., Marder S.R. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol. Psychiatry 2011, 69:442-449.
7. Buchanan R.W., Keefe R.S., Umbricht D., Green M.F., Laughren T., Marder S.R. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5years later?. Schizophr. Bull. 2011, 37:1209-1217.
8. Cho W., Maruff P., Connell J., Gargano C., Calder N., Doran S., Fox-Bosetti S., Hassan A., Renger J., Herman G., Lines C., Verma A. Additive effects of acholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology (Berl) 2011, 218:513-524.
9. Egan M., Yaari R., Liu L., Ryan M., Peng Y., Lines C., Michelson D. Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD. Curr. Alzheimer Res. 2012, 9:481-490.
10. Elvevåg B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 2000, 14:1-21.
11. Esbenshade T.A., Fox G.B., Cowart M.D. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol. Interv. 2006, 6:77-88.
12. Fox G.B., Esbenshade T.A., Pan J.B., Radek R.J., Krueger K.M., Yao B.B., Browman K.E., Buckley M.J., Ballard M.E., Komater V.A., Miner H., Zhang M., Faghih R., Rueter L.E., Bitner R.S., Drescher K.U., Wetter J., Marsh K., Lemaire M., Porsolt R.D., Bennani Y.L., Sullivan J.P., Cowart M.D., Decker M.W., Hancock A.A. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2 Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther. 2005, 313(1):176-190.
13. Gemkow M.J., Davenport A.J., Harich S., Ellenbroek B.A., Cesura A., Hallett D. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov. Today 2009, 14:509-515.
14. Goff D.C., Hill M., Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol. Biochem. Behav. 2011, 99:245-253.
15. Green M.F. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26:119-136.
16. Gur R.C., Ragland J.D., Moberg P.J., Turner T.H., Bilker W.B., Kohler C., Siegel S.J., Gur R.E. Computerized neurocognitive scanning: I. Methodology and validation in healthy people. Neuropsychopharmacology 2001, 25:766-776.
17. Gur R.C., Ragland J.D., Moberg P.J., Bilker W.B., Kohler C., Siegel S.J., Gur R.E. Computerized neurocognitive scanning: II. The profile of schizophrenia. Neuropsychopharmacology 2001, 25:777-788.
18. Gur R.C., Richard J., Hughett P., Calkins M.E., Macy L., Bilker W.B., Brensinger C., Gur R.E. A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation. J. Neurosci. Methods 2010, 187:254-262.
19. Guy W. Clinical Global Impressions New Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology 1976, 218-222. National Institute of Mental Health, Rockville, MD.
20. Herring W.J., Hutzelmann J., Liu K., Ceesay P., Snavely D., Snyder E., et al. The histamine inverse agonist ML-0249 in obstructive sleep apnea patients on CPAP with excessive daytime sleepiness: a randomized, controlled, adaptive crossover study. Sleep 2010, 33:A272.
21. Herring W.J., Wilens T.E., Adler L.A., Baranak C., Liu K., Snavely D.B., Lines C.R., Michelson D. Randomized controlled study of the histamine inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder. J Clin Psychiat 2012, 73:e891-8.
22. Hill S.K., Bishop J.R., Palumbo D., Sweeney J.A. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert. Rev. Neurother. 2010, 10:43-57.
23. Iannone R., Palcza J., Renger J.J., Calder N., Cerchio K., Gottesdiener K., et al. Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers. Clin. Pharmacol. Ther. 2010, 88:831-839.
24. Irani F., Brensinger C.M., Richard J., Calkins M.E., Moberg P.J., Bilker W., Gur R.E., Gur R.C. Computerized neurocognitive test performance in schizophrenia: a lifespan analysis. Am. J. Geriatr. Psychiatry 2012, 20:41-52.
25. James L.M., Iannone R., Palcza J., Renger J.J., Calder N., Cerchio K., Gottesdiener K., Hargreaves R., Murphy M.G., Boyle J., Dijk D.J. Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers. Psychopharmacology (Berl) 2011, 215:643-653.
26. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
27. Keefe R.S.E., Fenton W.S. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr. Bull. 2007, 33:912-920.
28. Keefe R.S., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004, 68:283-297.
29. Keefe R.S., Bilder R.M., Harvey P.D., Davis S.M., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Miller D.D., Canive J.M., Adler L.W., Manschreck T.C., Swartz M., Rosenheck R., Perkins D.O., Walker T.M., Stroup T.S., McEvoy J.P., Lieberman J.A. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006, 31:2033-2046.
30. Keefe R.S., Poe M., Walker T.M., Harvey P.D. The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and realworld functional outcome. J. Clin. Exp. Neuropsychol. 2006, 28:260-269.
31. Keefe R.S., Sweeney J.A., Gu H., Hamer R.M., Perkins D.O., McEvoy J.P., Lieberman J.A. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 2007, 164:1061-1071.
32. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., Jayathilake K., Meltzer H.Y., Roth B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526.
33. Liang K.Y., Zeger S.L. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya Ser. B 2000, 62:134-148.
34. Nagase T., Mizutani T., Ishikawa S., Sekino E., Sasaki T., Fujimura T., Ito S., Mitobe Y., Miyamoto Y., Yoshimoto R., Tanaka T., Ishihara A., Takenaga N., Tokita S., Fukami T., Sato N. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists. J. Med. Chem. 2008, 51:4780-4789.
35. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72:29-39.
36. Saykin A.J., Shtasel D.L., Gur R.E., Kester D.B., Mozley L.H., Stafiniak P., Gur R.C. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry 1994, 51:124-131.
37. Schwartz J.C. Histaminergic mechanisms in brain. Annu. Rev. Pharmacol. Toxicol. 1977, 17:325-339.
38. Schwartz J.C. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br. J. Pharmacol. 2011, 163:713-721.
39. Wada H., Inagaki N., Itowi N., Yamatodani A. Histaminergic neuron system in the brain: distribution and possible functions. Brain Res. Bull. 1991, 27:367-370.
40. Zoethout R.W., Iannone R., Bloem B.R., Palcza J., Murphy G., Chodakewitz J., Buntinx A., Gottesdiener K., Marsilio S., Rosen L., van Dyck K., Louis E.D., Cohen A.F., Schoemaker R.C., Tokita S., Sato N., Koblan K.S., Hargreaves R.H., Renger J.J., van Gerven J.M. The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol. J. Psychopharmacol. 2012, 26:292-302.